Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Awakn Life Sciences Corp (OP:AWKNF)

0.0650 UNCHANGED
Last Price Updated: 3:11 PM EST, Dec 13, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Awakn Life Sciences Corp

< Previous 1 2 3 4 5 Next >
Awakn Life Sciences Seeks To Treat Addictions: Gambling, Binge Eating And Compulsive Sexual Behavior
Awakn Life Sciences (OTC: AWKNF) is not only going after alcoholism but also binge eating disorder, compulsive sexual behavior and even Internet gaming disorder. 
Via Benzinga
This Ketamine-Assisted Therapy Company Is Developing New Ways To Treat Alcohol Addiction
Picture credit: Martin Sanchez on Unsplash This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. 
Via Benzinga
Psychedelic And Cannabis Drug Stocks Continue Advance
This article updates the performances of 16 clinical-stage psychedelic and marijuana drug companies researching the treatment of a wide variety of mental illnesses. 
Via Talk Markets
Mindset Pharma, Cybin Among Top Psychedelic Movers Of Today
GAINERS: Awakn Life Sciences (OTC:AWKNF) shares closed up 3.51% at $1.62 
Via Benzinga
Mind Medicine, Allied Among Top Psychedelic Movers Of Today
GAINERS: Small Pharma (OTC:DMTTF) shares closed up 5.04% at $0.17 
Via Benzinga
Awakn Life Sciences: Wake Up To The Huge Potential
The private global addiction treatment industry is currently valued at US$17.5 billion per year and forecast to increase to US$31.5 billion per year by 2027. 
Via Talk Markets
Has A Sugar Daddy Emerged In The Psychedelic Drug Industry?
One very large drug multinational has already been active in writing checks to finance drug development in the psychedelic drug industry. 
Via Talk Markets
The Psychedelic & Marijuana Drug Stocks Index Dropped -30% In January
This article updates the performances of 16 clinical-stage psychedelic and marijuana drug companies researching the treatment of a wide variety of mental illnesses. 
Via Talk Markets
Mind Medicine, Small Pharma Among Top Psychedelic Movers Of Today
GAINERS: Mindset Pharma (OTC:MSSTF) shares closed up 6.29% at $0.49 
Via Benzinga
Psychedelic Stock Gainers And Losers From January 24, 2022
GAINERS: Field Trip Health (NASDAQ: 
Via Benzinga
Psychedelic Stock Gainers And Losers From January 21, 2022
GAINERS: GH Research (NASDAQ: 
Via Benzinga
Psychedelic Stock Gainers And Losers From January 20, 2022
GAINERS: Small Pharma (OTC: 
Via Benzinga
Revive Therapeutics, GH Research Among Top Psychedelic Movers Of Today
GAINERS: Revive Therapeutics (OTC: 
Via Benzinga
Psychedelic Stock Gainers And Losers From January 18, 2022
GAINERS: Cybin (AMEX: 
Via Benzinga
Psyched: Delix Raises $30M, New Ketamine Study For Alcohol Use Disorder, FDA Approves Ketamine Trial For ALS
New Awakn Study Shows Ketamine Has Potential To Treat Alcoholism Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: 
Via Benzinga
Ketamine Therapy Shows Potential In Treatment Of Alcohol Use Disorder, New Study Finds
Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB:AWKNF) publis... 
Via Benzinga
The Year In Review For Psychedelic Drug Stocks: 2021
2021 was two different 
Via Talk Markets
Marijuana & Psychedelic Compounds-Based Drug Stocks Now Down -16% YTD
A look at which index has done the best so far in December: the Marijuana Drug Stocks Index or the Psychedelic Compounds-Based Drug Stocks Index. 
Via Talk Markets
AWKNF: A Psychedelic's Stock Exhibiting Recent Price Appreciation
Awakn Health Sciences Corp's trading pattern over the past 10-day time span is an egregious example of a psychedelic stock that has exhibited recent price appreciation coupled with a surge in average... 
Via Talk Markets
Psychedelic Drug Stocks Continued To Decline Last Week
The 12 constituents in our Pure-Play Psychedelic Compounds-Based Drug Stocks Index declined -5.7% last week; it's now -16.1% so far in November. 
Via Talk Markets
New Options to Treat Alcohol Use Disorder
New Options to Treat Alcohol Use Disorder 
Via News Direct
Psychedelic Drug Stocks Have Plunged -10.6%, On Average, So Far In November
Our Pure-Play Psychedelic Compounds-Based Drug Stocks Index has declined -10.6% in the last 2 weeks; it's still up +7.8% since the end of September. 
Via Talk Markets
BioMedNewsBreaks – Mind Cure Health Inc.’s (CSE: MCUR) (OTCQX: MCURF) (FRA: 6MH) iSTRYM Opening New Revenue Source, Helping Fuel Further Growth, Expansion
Via Investor Brand Network
Compass Pathways Phase II Results: A Disappointment For Some, An Opportunity For Others
Compass Pathways reported 
Via Talk Markets
Mind Cure Health Inc. (CSE: MCUR) (OTCQX: MCURF) (FRA: 6MH) Growth Strategy Moves Forward with Awakn Life Sciences (NEO: AWKN) (OTCQB: AWKNF) Partnership for Ketamine-Assisted Psychotherapy Distribution
Via Investor Brand Network
Psyched: MindMed's MDMA Program For Autism, Small Pharma's New Patent, NovaMentis' Orphan Drug Designation
The Week In Psychedelics: 
Via Benzinga
Topics Intellectual Property
PsychedelicNewsBreaks – Mind Cure Health Inc. (CSE: MCUR) (OTCQX: MCURF) (FRA: 6MH) Enters Strategic LOI to Distribute Ketamine Protocol
Via Investor Brand Network
MINDCURE Signs LOI with Awakn Life Sciences to Distribute Ketamine Protocol for Alcohol Use Disorder into Clinics Across United States and Canada through iSTRYM, MINDCURE’s Digital Therapeutics Platform
Vancouver, BC – October 28, 2021 – Mind Cure Health Inc. (CSE: MCUR) (OTCQX: MCURF) (FRA: 6MH) (“MINDCURE” or the “Company”), a leader in advanced proprietary technology and research for psychedelics,... 
Via FinancialNewsMedia
Psyched: British PM Considers Psychedelics, New Partnership To Study Psilocybin For Autism, Compass Gets Another Patent
The Week In Psychedelics 
Via Benzinga
Psychedelic Stocks Rebounded 9% Last Week; Small Pharma Was Up 148%
The Psychedelic Compounds-Based Drug Stocks Index was up +8.9% last week albeit still down -18.5% YTD. 
Via Talk Markets
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.